XML 68 R36.htm IDEA: XBRL DOCUMENT

Collaboration and Licensing Revenue (Tables)

12 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December 31, 2020, 2019 and 2018.


	Year Ended December 31,
	2020		2019		2018
ZIOPHARM Oncology, Inc.	$	200	$	2,171	$	16,298
Ares Trading S.A.	—		—		11,175
Oragenics, Inc.	3,053		(564)		1,353
Intrexon T1D Partners, LLC	—		—		2,502
Intrexon Energy Partners, LLC	—		2,596		6,929
Intrexon Energy Partners II, LLC	—		1,217		2,998
Castle Creek Biosciences, Inc.	17,810		3,713		1,394


Harvest start-up entities (1)	—		4,862		14,447
Other	145		64		12,444
Total (2)	$	21,208	$	14,059	$	69,540

(1)For the years ended December 31, 2019 and 2018, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the year ended December 31, 2018, revenue recognized from collaborations with Harvest start-up entities also include Genten Therapeutics and CRS Bio.

(2)Collaboration and licensing revenues recognized for the years ended December 31, 2020, 2019 and 2018, include the recognition of $20,205, $7,505, and $39,446, respectively, associated with upfront and milestone payments which were previously deferred.

Summary of Deferred Revenue

Deferred revenue consisted of the following:


	December 31,
	2020		2019
Collaboration and licensing agreements	$	23,420	$	50,593
Prepaid product and service revenues	2,126		2,805
Other	277		435
Total	$	25,823	$	53,833
Current portion of deferred revenue	$	2,800	$	5,697
Long-term portion of deferred revenue	23,023		48,136
Total	$	25,823	$	53,833

Summary of Deferred Revenue by Collaborator

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of December 31, 2020 and 2019, as well as the estimated remaining performance period as of December 31, 2020.


	Average Remaining Performance Period (Years)	December 31,
		2020		2019
Oragenics, Inc.	0.0	$	—	$	2,864
Intrexon Energy Partners, LLC	3.2	8,362		8,362
Intrexon Energy Partners II, LLC	3.9	12,843		12,843
Castle Creek Biosciences, Inc.	1.0	379		17,697
Harvest start-up entities (1)	0.0	—		6,993
Other	2.2	1,836		1,834
Total		$	23,420	$	50,593

(1)As of December 31, 2019, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Exotech Bio, and AD Skincare.